ArticleAnnals of translational medicine2026
Impact of tobacco use on inpatient outcomes in inflammatory bowel disease: a retrospective matched cohort study.
Article in Annals of translational medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Comparative efficacy of ustekinumab and vedolizumab in anti-TNF-naive and anti-TNF-exposed patients with Crohn's disease: a matched cohort study.Proceedings (Baylor University. Medical Center) · 2026Article
- Predictive model for ulcerative colitis therapeutic response using clinical indicators and peripheral blood T-cell subsets.Frontiers in immunology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Tobacco plays a complex role in patients with inflammatory bowel disease (IBD). Its impact on inpatient outcomes of IBD needs additional study. We aimed to assess the impact of smoking on clinical outcomes in hospitalized patients with IBD. Methods: We conducted a retrospective cohort study using data from the National Inpatient Sample (NIS) spanning from 2016 to 2019. Patients with UC and CD were identified utilizing ICD-10 codes. Patients were stratified according to the smoking status in two groups. A propensity score matching was utilized to balance comorbidities between study groups. Study outcomes included rates of steroid use, surgeries, gastrointestinal (GI) bleeding, perianal abscess, and overall mortality. All outcomes were assessed during the index hospitalization. Statistical analysis was performed using Stata 17 software. Results were reported as adjusted odds ratios (aORs) with 95% confidence intervals (CIs). Results: A total of 413,208 patients were included in our study, 180,558 patients had UC, and 232,650 patients had CD. After propensity score matching, we had a total of 151,106 patients: 39,616 patients had UC, with a total of 19,808 in each group. The CD patients were 111,490, with a total of 55,745 patients in each group. For UC patients, smokers had lower odds of steroid use (aOR =0.69, 95% CI: 0.61-0.79, P=0.001), and all-cause mortality (aOR =0.54, 95% CI: 0.32-0.96, P=0.03). For CD patients, smokers had higher odds of steroid use (aOR =1.13, 95% CI: 1.03-1.25, P=0.009), perianal abscess (aOR =1.12, 95% CI: 1.10-1.36, P=0.02), and all-cause mortality (aOR =1.51, 95% CI: 1.27-1.84, P=0.04). All other outcomes were not significant between the study cohorts. Conclusions: Tobacco use in hospitalized patients with UC was associated with lower steroid use, while in patients with CD, it correlated with higher steroid use and increased odds of perianal abscesses. These findings highlight the complex impact of tobacco use on IBD outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.